Research Analysts Update Earnings Forecast for Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Free Report) has recently seen a revision in earnings estimates by equity research analysts at HC Wainwright. In a report released on March 19, 2025, analyst S. Ramakanth lowered the company's projected earnings for the second quarter of 2025. The new expectation is that Eton will report earnings of $0.08 per share, a decline from the earlier estimate of $0.17. Despite this adjustment, HC Wainwright maintains a “Buy” rating for the stock and sets a price target of $33.00.

For the current fiscal year, the consensus forecast for Eton Pharmaceuticals suggests expected earnings of ($0.14) per share. Analysts from HC Wainwright also provided estimates for upcoming quarters: $0.11 EPS for Q3 2025, $0.18 EPS for Q4 2025, totaling $0.42 EPS for the entire FY2025. Looking further ahead, predictions include $1.57 EPS for FY2026, $1.85 EPS for FY2027, $2.87 EPS for FY2028, and $3.74 EPS for FY2029.

Recent Commentary from Other Analysts

Other market analysts have expressed their views on Eton Pharmaceuticals. B. Riley reaffirmed a “buy” rating, raising its target price from $21.00 to $24.00. Additionally, Craig Hallum updated its target price from $23.00 to $26.00 while maintaining a “buy” rating on Eton shares.

On March 22, 2025, Eton’s stock opened at $14.22, reflecting a decrease of 3.8%. The one-year trading range for the stock is between a low of $3.03 and a high of $18.41. Eton Pharmaceuticals currently has a market capitalization of $370.45 million, with a P/E ratio of -64.64 and a beta of 1.37. The stock’s fifty-day moving average is $15.58, while its two-hundred-day moving average stands at $11.54.

Quarterly Financial Performance

The company recently reported its quarterly earnings on March 18, 2025. In this report, Eton posted earnings of ($0.02) per share, which aligns with the consensus estimate. The firm reported a revenue of $11.65 million for the quarter, exceeding the anticipated figure of $10.53 million. However, Eton also faced challenges with a negative net margin of 15.81% and a negative return on equity measuring 36.29%.

Institutional Investment Activity

Recent data shows that several institutional investors have adjusted their holdings in Eton Pharmaceuticals. Notably, Nantahala Capital Management LLC increased its stake by 12.0% during the last quarter, now owning 1,118,483 shares valued at approximately $14.9 million following the acquisition of an additional 119,750 shares. Westside Investment Management Inc. also grew its position by 5.7% during the third quarter, totaling 618,675 shares worth around $3.71 million. Additional investments include new stakes from Mink Brook Asset Management LLC and Cannell Capital LLC, both acquired in the last quarter.

Currently, institutional investors own about 27.86% of Eton Pharmaceuticals' stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. specializes in developing, acquiring, and commercializing pharmaceutical products aimed at treating rare diseases. The company's product offerings include ALKINDI SPRINKLE, which is a replacement therapy for children suffering from adrenocortical insufficiency, Carglumic Acid for managing acute and chronic hyperammonemia, Betaine Anhydrous for treating homocystinuria, and Nitisinone for treating tyrosinemia type 1.

Earnings, Estimates, Stock